董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Sijmen de Vries | 男 | Non-Executive Director | 66 | 4.00万 | 1620.00 | 2026-01-05 |
| Stephen Stamp | 男 | Chief Executive Officer and Director | 65 | 30.31万 | 4837.26 | 2026-01-05 |
| Stephen Parker | 男 | Non-Executive Chairman of the Board | 68 | 8.20万 | 3240.00 | 2026-01-05 |
| Ann Merchant | 女 | Non-Executive Director | 61 | 4.00万 | 1620.00 | 2026-01-05 |
| Fiona Sharp | 女 | Chief Financial Officer, Corporate Secretary and Director | 57 | 未披露 | 1612.65 | 2026-01-05 |
| Simon Turton | 男 | Senior Independent Non-Executive Director | 59 | 4.00万 | 1620.28 | 2026-01-05 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Stephen Stamp | 男 | Chief Executive Officer and Director | 65 | 30.31万 | 4837.26 | 2026-01-05 |
| Fiona Sharp | 女 | Chief Financial Officer, Corporate Secretary and Director | 57 | 未披露 | 1612.65 | 2026-01-05 |
董事简历
中英对照 | 中文 | 英文- Sijmen de Vries
-
Sijmen de Vries，他曾一直担任 Midatech公司的董事会的非执行成员（2004年10月以来），包括任职Midatech公司的前任实体。他曾担任Pharming Group NV （Euronext：PHARM） 的首席执行官（2008年11月以来）。此前，他曾担任4-Antibody公司和Morphochem AG的首席执行官。此前，他曾任职Novartis Pharma公司、Novartis Ophthalmics公司、SmithKline Beecham Pharmaceuticals公司，在那里他曾担任高级业务商业职务。他持有the University of Amsterdam的医学博士学位，以及Ashridge Management College（位于英国）的综合管理方面的工商管理硕士学位。
Sijmen de Vries has served as a non executive member of Board of Directors since October 2004 (including his service to predecessor entity). From November 2008 until March 2025, Dr. de Vries has served as of the Chief Executive Officer of Pharming Group NV (Euronext: PHARM). Prior to that, Dr. de Vries served as Chief Executive Officer of 4 Antibody and Morphochem AG. Prior to this he worked at Novartis Pharma, Novartis Ophthalmics and at SmithKline Beecham Pharmaceuticals Plc, where he held senior business and commercial positions. Dr. de Vries holds an M.D. degree from the University of Amsterdam and a Masters of Business Administration in General Management from Ashridge Management College (United Kingdom). - Sijmen de Vries，他曾一直担任 Midatech公司的董事会的非执行成员（2004年10月以来），包括任职Midatech公司的前任实体。他曾担任Pharming Group NV （Euronext：PHARM） 的首席执行官（2008年11月以来）。此前，他曾担任4-Antibody公司和Morphochem AG的首席执行官。此前，他曾任职Novartis Pharma公司、Novartis Ophthalmics公司、SmithKline Beecham Pharmaceuticals公司，在那里他曾担任高级业务商业职务。他持有the University of Amsterdam的医学博士学位，以及Ashridge Management College（位于英国）的综合管理方面的工商管理硕士学位。
- Sijmen de Vries has served as a non executive member of Board of Directors since October 2004 (including his service to predecessor entity). From November 2008 until March 2025, Dr. de Vries has served as of the Chief Executive Officer of Pharming Group NV (Euronext: PHARM). Prior to that, Dr. de Vries served as Chief Executive Officer of 4 Antibody and Morphochem AG. Prior to this he worked at Novartis Pharma, Novartis Ophthalmics and at SmithKline Beecham Pharmaceuticals Plc, where he held senior business and commercial positions. Dr. de Vries holds an M.D. degree from the University of Amsterdam and a Masters of Business Administration in General Management from Ashridge Management College (United Kingdom).
- Stephen Stamp
-
Stephen Stamp，2017年12月至2019年1月担任Ergomed PLC（AIM：ERGO）首席执行官，2016年1月至2018年7月担任首席财务官。2013年3月至2015年7月，Stamp先生担任Assurex Health，Inc.的首席财务官。Stamp先生于2010年11月至2012年10月以及2010年3月至2010年6月担任EZCORP Inc.（纳斯达克股票代码：EZPW）和KV Pharmaceuticals Co.的首席财务官。Stamp先生此前还曾担任Xanodyne Pharmaceuticals，Inc.的首席运营官，Regus PLC（现为IWG plc）（LON：IWG）和Shire plc（后被Takeda Pharmaceuticals Company Limited收购）的集团财务总监。Stamp先生是一名特许会计师，具有毕马威会计师事务所（KPMG LLP）的资格。Stamp先生拥有曼彻斯特大学经济学学士学位。
Stephen Stamp has served as Chief Executive Officer since March 31, 2020, and Chief Financial Officer and a member of Board of Directors since September 2019. Prior to joining the Company, Mr. Stamp served as Chief Executive Officer of Ergomed plc (AIM: ERGO) from December 2017 until January 2019 and Chief Financial Officer from January 2016 to July 2018. From March 2013 until July 2015, Mr. Stamp served as the Chief Financial Officer of Assurex Health, Inc. Mr. Stamp served as Chief Financial Officer of EZCORP Inc. (NASDAQ: EZPW) and KV Pharmaceuticals Co. from November 2010 to October 2012 and March 2010 to June 2010. Mr. Stamp has also previously served as Chief Operating Officer of Xanodyne Pharmaceuticals, Inc., and Group Finance Director of Regus PLC (now IWG plc) (LON: IWG) and Shire plc (subsequently acquired by Takeda Pharmaceuticals Company Limited). Mr. Stamp is a Chartered Accountant and qualified with KPMG LLP. Mr. Stamp has a Bachelor's degree in economics from the University of Manchester. - Stephen Stamp，2017年12月至2019年1月担任Ergomed PLC（AIM：ERGO）首席执行官，2016年1月至2018年7月担任首席财务官。2013年3月至2015年7月，Stamp先生担任Assurex Health，Inc.的首席财务官。Stamp先生于2010年11月至2012年10月以及2010年3月至2010年6月担任EZCORP Inc.（纳斯达克股票代码：EZPW）和KV Pharmaceuticals Co.的首席财务官。Stamp先生此前还曾担任Xanodyne Pharmaceuticals，Inc.的首席运营官，Regus PLC（现为IWG plc）（LON：IWG）和Shire plc（后被Takeda Pharmaceuticals Company Limited收购）的集团财务总监。Stamp先生是一名特许会计师，具有毕马威会计师事务所（KPMG LLP）的资格。Stamp先生拥有曼彻斯特大学经济学学士学位。
- Stephen Stamp has served as Chief Executive Officer since March 31, 2020, and Chief Financial Officer and a member of Board of Directors since September 2019. Prior to joining the Company, Mr. Stamp served as Chief Executive Officer of Ergomed plc (AIM: ERGO) from December 2017 until January 2019 and Chief Financial Officer from January 2016 to July 2018. From March 2013 until July 2015, Mr. Stamp served as the Chief Financial Officer of Assurex Health, Inc. Mr. Stamp served as Chief Financial Officer of EZCORP Inc. (NASDAQ: EZPW) and KV Pharmaceuticals Co. from November 2010 to October 2012 and March 2010 to June 2010. Mr. Stamp has also previously served as Chief Operating Officer of Xanodyne Pharmaceuticals, Inc., and Group Finance Director of Regus PLC (now IWG plc) (LON: IWG) and Shire plc (subsequently acquired by Takeda Pharmaceuticals Company Limited). Mr. Stamp is a Chartered Accountant and qualified with KPMG LLP. Mr. Stamp has a Bachelor's degree in economics from the University of Manchester.
- Stephen Parker
-
Stephen Parker，在医疗保健和制药领域的职业生涯跨越30多年，其中10年担任顾问职务。Parker博士自2002年起担任SP2 Consulting Limited的董事总经理，并自2019年起担任Opus Corporate Finance LLP的顾问。Parker博士还自2016年5月起担任Sareum Holdings PLC（AIM：SAR）的董事长，自2021年1月起担任Drishti Discoveries Limited的董事长，自2019年3月起担任MGC Pharmaceuticals Limited（ASX，LSE：MXC）的高级独立董事，自2019年7月起担任Eternans Limited的董事，自2018年9月起担任SP2 Asset Management Limited的董事。此前，Parker博士于2013年9月至2019年9月期间担任Albucasis Limited的董事，于2017年7月至2018年7月期间担任Liverpool Chirochem Limited的董事长，并于2013年11月至2019年4月期间担任Silence Therapeutics PLC（LSE：SLN）的董事兼董事长。Parker博士还拥有企业融资经验，曾在Barings Brothers Limited、SBC Warburg Dillon Read和Apax Partners LLP担任专注于制药和生物技术的投资银行家，此前曾担任Celtic Pharma GP Limited子公司的董事和Oxford GlycoSciences的首席财务官。Parker博士在牛津大学获得生物化学博士学位，在伦敦城市大学获得工商管理MBA学位，在东英吉利大学获得化学科学学士学位。
Stephen Parker has served as Non Executive Chairman of the Board of Directors and a director since June 2022. Dr. Parker has a career in the healthcare and pharma sector that spans over 30 years, including 10 years in advisory roles. Dr. Parker has served as Managing Director of sp2 Consulting Limited since September 2002. Dr. Parker has also served as Chairman of Sareum Holdings plc (AIM: SAR) since May 2016, Drishti Discoveries Limited since January 2021 and sp2 Asset Management Limited since September 2018. Previously, Dr. Parker served as a director of Albucasis Limited from September 2013 to September 2019, as Chairman of Liverpool Chirochem Limited from July 2017 to July 2018, as Senior Independent Director of MGC Pharmaceuticals Limited (ASX, LSE:MXC) from March 2019 to November 2023, as a director of Eternans Limited from July 2019 to October 2023 and as a director and Chairman of Silence Therapeutics plc (LSE: SLN) from November 2013 to April 2019. Dr. Parker also has corporate finance experience having been an investment banker focusing on pharma and biotechnology with Barings Brothers Limited, SBC Warburg Dillon Read, and Apax Partners LLP, and previously served as a director at subsidiaries of Celtic Pharma GP Limited and Chief Financial Officer of Oxford GlycoSciences. Dr. Parker received his D.Phil in Biochemistry from the University of Oxford, MBA in Business Administration from City University, London, and B.Sc. in Chemical Sciences from the University of East Anglia. - Stephen Parker，在医疗保健和制药领域的职业生涯跨越30多年，其中10年担任顾问职务。Parker博士自2002年起担任SP2 Consulting Limited的董事总经理，并自2019年起担任Opus Corporate Finance LLP的顾问。Parker博士还自2016年5月起担任Sareum Holdings PLC（AIM：SAR）的董事长，自2021年1月起担任Drishti Discoveries Limited的董事长，自2019年3月起担任MGC Pharmaceuticals Limited（ASX，LSE：MXC）的高级独立董事，自2019年7月起担任Eternans Limited的董事，自2018年9月起担任SP2 Asset Management Limited的董事。此前，Parker博士于2013年9月至2019年9月期间担任Albucasis Limited的董事，于2017年7月至2018年7月期间担任Liverpool Chirochem Limited的董事长，并于2013年11月至2019年4月期间担任Silence Therapeutics PLC（LSE：SLN）的董事兼董事长。Parker博士还拥有企业融资经验，曾在Barings Brothers Limited、SBC Warburg Dillon Read和Apax Partners LLP担任专注于制药和生物技术的投资银行家，此前曾担任Celtic Pharma GP Limited子公司的董事和Oxford GlycoSciences的首席财务官。Parker博士在牛津大学获得生物化学博士学位，在伦敦城市大学获得工商管理MBA学位，在东英吉利大学获得化学科学学士学位。
- Stephen Parker has served as Non Executive Chairman of the Board of Directors and a director since June 2022. Dr. Parker has a career in the healthcare and pharma sector that spans over 30 years, including 10 years in advisory roles. Dr. Parker has served as Managing Director of sp2 Consulting Limited since September 2002. Dr. Parker has also served as Chairman of Sareum Holdings plc (AIM: SAR) since May 2016, Drishti Discoveries Limited since January 2021 and sp2 Asset Management Limited since September 2018. Previously, Dr. Parker served as a director of Albucasis Limited from September 2013 to September 2019, as Chairman of Liverpool Chirochem Limited from July 2017 to July 2018, as Senior Independent Director of MGC Pharmaceuticals Limited (ASX, LSE:MXC) from March 2019 to November 2023, as a director of Eternans Limited from July 2019 to October 2023 and as a director and Chairman of Silence Therapeutics plc (LSE: SLN) from November 2013 to April 2019. Dr. Parker also has corporate finance experience having been an investment banker focusing on pharma and biotechnology with Barings Brothers Limited, SBC Warburg Dillon Read, and Apax Partners LLP, and previously served as a director at subsidiaries of Celtic Pharma GP Limited and Chief Financial Officer of Oxford GlycoSciences. Dr. Parker received his D.Phil in Biochemistry from the University of Oxford, MBA in Business Administration from City University, London, and B.Sc. in Chemical Sciences from the University of East Anglia.
- Ann Merchant
-
Ann Merchant，自2018年起担任MorphoSys AG（NASDAQ：MOR）副总裁，该公司是一家商业阶段的生物制药公司，总部位于德国慕尼黑，自2019年1月起担任全球供应链和外部运营主管。2011年9月至2018年8月，Merchant女士担任Schreimer Mediparm的总裁，该公司是Schreimer Group GmbH & Co. KG的一个业务部门。1994年至2011年期间，Merchant女士在安进公司（纳斯达克股票代码：AMGN）担任过多个职务，包括2007年至2011年期间的副总裁、国际供应链主管和现场主管。Merchant女士目前担任生物仿制药公司Alvotech S.A.（纳斯达克股票代码：ALVO）的董事会成员。Merchant女士拥有亨利商学院的MBA学位和乔治城大学的语言理学学士学位。
Ann Merchant has served as a non executive member of Board of Directors since December 2023. Ms. Merchant has served as Vice President for MorphoSys AG (NASDAQ: MOR), a commercial stage biopharmaceutical company headquartered in Munich, Germany, since 2018, and as Head of Supply Chain and External Operations since January 2019 until April 2025. From September 2011 to August 2018, Ms. Merchant served as the President for Schreiner Medipharm, a business unit of the Schreiner Group Gmbh & Co. KG. Between 1994 and 2011, Ms. Merchant held various roles at Amgen Inc. (NASDAQ: AMGN), including Vice President, Head of International Supply Chain and Site Head as well as various roles in the Finance Organization between 2007 and 2011. Ms. Merchant currently serves on the board of directors of Alvotech S.A. (NASDAQ: ALVO), a biosimilar company. Ms. Merchant holds an MBA from the Henley Business School and a Bachelor of Science in Languages from Georgetown University. - Ann Merchant，自2018年起担任MorphoSys AG（NASDAQ：MOR）副总裁，该公司是一家商业阶段的生物制药公司，总部位于德国慕尼黑，自2019年1月起担任全球供应链和外部运营主管。2011年9月至2018年8月，Merchant女士担任Schreimer Mediparm的总裁，该公司是Schreimer Group GmbH & Co. KG的一个业务部门。1994年至2011年期间，Merchant女士在安进公司（纳斯达克股票代码：AMGN）担任过多个职务，包括2007年至2011年期间的副总裁、国际供应链主管和现场主管。Merchant女士目前担任生物仿制药公司Alvotech S.A.（纳斯达克股票代码：ALVO）的董事会成员。Merchant女士拥有亨利商学院的MBA学位和乔治城大学的语言理学学士学位。
- Ann Merchant has served as a non executive member of Board of Directors since December 2023. Ms. Merchant has served as Vice President for MorphoSys AG (NASDAQ: MOR), a commercial stage biopharmaceutical company headquartered in Munich, Germany, since 2018, and as Head of Supply Chain and External Operations since January 2019 until April 2025. From September 2011 to August 2018, Ms. Merchant served as the President for Schreiner Medipharm, a business unit of the Schreiner Group Gmbh & Co. KG. Between 1994 and 2011, Ms. Merchant held various roles at Amgen Inc. (NASDAQ: AMGN), including Vice President, Head of International Supply Chain and Site Head as well as various roles in the Finance Organization between 2007 and 2011. Ms. Merchant currently serves on the board of directors of Alvotech S.A. (NASDAQ: ALVO), a biosimilar company. Ms. Merchant holds an MBA from the Henley Business School and a Bachelor of Science in Languages from Georgetown University.
- Fiona Sharp
-
Fiona Sharp，自2019年12月起担任公司集团财务总监。在此之前，她曾于2018年10月至2019年7月担任Hywell DDA大学健康委员会的财务助理主任，该委员会是威尔士National Health服务于英国西威尔士的地方健康委员会。从1995年到2018年6月，夏普女士在总部位于伦敦的国际传播和体育营销集团Chime Communications Limited担任过多个财务领导职务，包括集团税务顾问和集团财务总监。夏普女士是一名特许注册会计师。
Fiona Sharp has served as Group Financial Controller of the Company since December 2019 and a member of Board of Directors since January 2026. Prior to that, she served as Assistant Director of Finance for Hywell DDA University Health Board, a local health board of the National Health Service of Wales for western Wales, United Kingdom, from October 2018 to July 2019. From 1995 to June 2018, Ms. Sharp held various financial leadership roles with Chime Communications Limited, a London based international communications and sports marketing group, including Group Tax Consultant and Group Finance Director. Ms. Sharp is a Chartered Certified Accountant. - Fiona Sharp，自2019年12月起担任公司集团财务总监。在此之前，她曾于2018年10月至2019年7月担任Hywell DDA大学健康委员会的财务助理主任，该委员会是威尔士National Health服务于英国西威尔士的地方健康委员会。从1995年到2018年6月，夏普女士在总部位于伦敦的国际传播和体育营销集团Chime Communications Limited担任过多个财务领导职务，包括集团税务顾问和集团财务总监。夏普女士是一名特许注册会计师。
- Fiona Sharp has served as Group Financial Controller of the Company since December 2019 and a member of Board of Directors since January 2026. Prior to that, she served as Assistant Director of Finance for Hywell DDA University Health Board, a local health board of the National Health Service of Wales for western Wales, United Kingdom, from October 2018 to July 2019. From 1995 to June 2018, Ms. Sharp held various financial leadership roles with Chime Communications Limited, a London based international communications and sports marketing group, including Group Tax Consultant and Group Finance Director. Ms. Sharp is a Chartered Certified Accountant.
- Simon Turton
-
Simon Turton，2014年12月起，担任Midatech的非执行董事。他从2014年3月起，担任的董事长，直到2014年12月它们被Midatech收购。2015年1月起，他担任Gensmile Limited的总经理。2002年，他加入，最后的职务是欧洲地区医疗保健行业投资业务总监，直到2011年6月。他曾担任Archimedes Pharma、Eurand、ProStrakan Group plc 、Tornier, Inc.（NASDAQ： TRNX）的董事。他在INSEAD获得工商管理硕士学位，在University of London获得药剂学博士学位。
Simon Turton has served as a non executive member of Board of Directors since December 2014. Dr. Turton served as Chairman of Q Chip and OpsiRx Pharmaceuticals from March 2014 until their acquisition by in December 2014. Since January 2015, he has served as the Managing Director of Gensmile Limited. In 2002, Dr. Turton joined Warburg Pincus', most recently as head of healthcare investing activities in Europe, until June 2011. Dr. Turton has previously served on the board of Archimedes Pharma, Eurand, ProStrakan Group plc and Tornier, Inc. Dr. Turton has a Master's of Business Administration from INSEAD and a Ph.D. in Pharmacy from the University of London. Dr. Turton. - Simon Turton，2014年12月起，担任Midatech的非执行董事。他从2014年3月起，担任的董事长，直到2014年12月它们被Midatech收购。2015年1月起，他担任Gensmile Limited的总经理。2002年，他加入，最后的职务是欧洲地区医疗保健行业投资业务总监，直到2011年6月。他曾担任Archimedes Pharma、Eurand、ProStrakan Group plc 、Tornier, Inc.（NASDAQ： TRNX）的董事。他在INSEAD获得工商管理硕士学位，在University of London获得药剂学博士学位。
- Simon Turton has served as a non executive member of Board of Directors since December 2014. Dr. Turton served as Chairman of Q Chip and OpsiRx Pharmaceuticals from March 2014 until their acquisition by in December 2014. Since January 2015, he has served as the Managing Director of Gensmile Limited. In 2002, Dr. Turton joined Warburg Pincus', most recently as head of healthcare investing activities in Europe, until June 2011. Dr. Turton has previously served on the board of Archimedes Pharma, Eurand, ProStrakan Group plc and Tornier, Inc. Dr. Turton has a Master's of Business Administration from INSEAD and a Ph.D. in Pharmacy from the University of London. Dr. Turton.
高管简历
中英对照 | 中文 | 英文- Stephen Stamp
Stephen Stamp，2017年12月至2019年1月担任Ergomed PLC（AIM：ERGO）首席执行官，2016年1月至2018年7月担任首席财务官。2013年3月至2015年7月，Stamp先生担任Assurex Health，Inc.的首席财务官。Stamp先生于2010年11月至2012年10月以及2010年3月至2010年6月担任EZCORP Inc.（纳斯达克股票代码：EZPW）和KV Pharmaceuticals Co.的首席财务官。Stamp先生此前还曾担任Xanodyne Pharmaceuticals，Inc.的首席运营官，Regus PLC（现为IWG plc）（LON：IWG）和Shire plc（后被Takeda Pharmaceuticals Company Limited收购）的集团财务总监。Stamp先生是一名特许会计师，具有毕马威会计师事务所（KPMG LLP）的资格。Stamp先生拥有曼彻斯特大学经济学学士学位。
Stephen Stamp has served as Chief Executive Officer since March 31, 2020, and Chief Financial Officer and a member of Board of Directors since September 2019. Prior to joining the Company, Mr. Stamp served as Chief Executive Officer of Ergomed plc (AIM: ERGO) from December 2017 until January 2019 and Chief Financial Officer from January 2016 to July 2018. From March 2013 until July 2015, Mr. Stamp served as the Chief Financial Officer of Assurex Health, Inc. Mr. Stamp served as Chief Financial Officer of EZCORP Inc. (NASDAQ: EZPW) and KV Pharmaceuticals Co. from November 2010 to October 2012 and March 2010 to June 2010. Mr. Stamp has also previously served as Chief Operating Officer of Xanodyne Pharmaceuticals, Inc., and Group Finance Director of Regus PLC (now IWG plc) (LON: IWG) and Shire plc (subsequently acquired by Takeda Pharmaceuticals Company Limited). Mr. Stamp is a Chartered Accountant and qualified with KPMG LLP. Mr. Stamp has a Bachelor's degree in economics from the University of Manchester.- Stephen Stamp，2017年12月至2019年1月担任Ergomed PLC（AIM：ERGO）首席执行官，2016年1月至2018年7月担任首席财务官。2013年3月至2015年7月，Stamp先生担任Assurex Health，Inc.的首席财务官。Stamp先生于2010年11月至2012年10月以及2010年3月至2010年6月担任EZCORP Inc.（纳斯达克股票代码：EZPW）和KV Pharmaceuticals Co.的首席财务官。Stamp先生此前还曾担任Xanodyne Pharmaceuticals，Inc.的首席运营官，Regus PLC（现为IWG plc）（LON：IWG）和Shire plc（后被Takeda Pharmaceuticals Company Limited收购）的集团财务总监。Stamp先生是一名特许会计师，具有毕马威会计师事务所（KPMG LLP）的资格。Stamp先生拥有曼彻斯特大学经济学学士学位。
- Stephen Stamp has served as Chief Executive Officer since March 31, 2020, and Chief Financial Officer and a member of Board of Directors since September 2019. Prior to joining the Company, Mr. Stamp served as Chief Executive Officer of Ergomed plc (AIM: ERGO) from December 2017 until January 2019 and Chief Financial Officer from January 2016 to July 2018. From March 2013 until July 2015, Mr. Stamp served as the Chief Financial Officer of Assurex Health, Inc. Mr. Stamp served as Chief Financial Officer of EZCORP Inc. (NASDAQ: EZPW) and KV Pharmaceuticals Co. from November 2010 to October 2012 and March 2010 to June 2010. Mr. Stamp has also previously served as Chief Operating Officer of Xanodyne Pharmaceuticals, Inc., and Group Finance Director of Regus PLC (now IWG plc) (LON: IWG) and Shire plc (subsequently acquired by Takeda Pharmaceuticals Company Limited). Mr. Stamp is a Chartered Accountant and qualified with KPMG LLP. Mr. Stamp has a Bachelor's degree in economics from the University of Manchester.
- Fiona Sharp
Fiona Sharp，自2019年12月起担任公司集团财务总监。在此之前，她曾于2018年10月至2019年7月担任Hywell DDA大学健康委员会的财务助理主任，该委员会是威尔士National Health服务于英国西威尔士的地方健康委员会。从1995年到2018年6月，夏普女士在总部位于伦敦的国际传播和体育营销集团Chime Communications Limited担任过多个财务领导职务，包括集团税务顾问和集团财务总监。夏普女士是一名特许注册会计师。
Fiona Sharp has served as Group Financial Controller of the Company since December 2019 and a member of Board of Directors since January 2026. Prior to that, she served as Assistant Director of Finance for Hywell DDA University Health Board, a local health board of the National Health Service of Wales for western Wales, United Kingdom, from October 2018 to July 2019. From 1995 to June 2018, Ms. Sharp held various financial leadership roles with Chime Communications Limited, a London based international communications and sports marketing group, including Group Tax Consultant and Group Finance Director. Ms. Sharp is a Chartered Certified Accountant.- Fiona Sharp，自2019年12月起担任公司集团财务总监。在此之前，她曾于2018年10月至2019年7月担任Hywell DDA大学健康委员会的财务助理主任，该委员会是威尔士National Health服务于英国西威尔士的地方健康委员会。从1995年到2018年6月，夏普女士在总部位于伦敦的国际传播和体育营销集团Chime Communications Limited担任过多个财务领导职务，包括集团税务顾问和集团财务总监。夏普女士是一名特许注册会计师。
- Fiona Sharp has served as Group Financial Controller of the Company since December 2019 and a member of Board of Directors since January 2026. Prior to that, she served as Assistant Director of Finance for Hywell DDA University Health Board, a local health board of the National Health Service of Wales for western Wales, United Kingdom, from October 2018 to July 2019. From 1995 to June 2018, Ms. Sharp held various financial leadership roles with Chime Communications Limited, a London based international communications and sports marketing group, including Group Tax Consultant and Group Finance Director. Ms. Sharp is a Chartered Certified Accountant.